Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRC 4016 (Icosabutate) Phase I in Healthy Subjects
NCT02364635Phase 1Completed
- Sponsor
- Pronova BioPharma
- Start
- Feb 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of icosabutate in mixed dyslipidemia and hypertriglyceridemia (5 arms), sponsored by Pronova BioPharma. Primary endpoints: Area Under the Curve, Maximum Plasma Concentration and 1 more. Started Feb 2015; status: completed.
02
Drugs
icosabutate
03
Conditions
mixed dyslipidemiahypertriglyceridemia
Beyond the preview
Go deeper on NCT02364635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02364635.